Session 11 – From Precision Medicine to Precision Health
Date: 24 July (Friday) 10:40 – 12:10 (GMT+8)
Venue: 701EF, 7F, TaiNEX2 / Online event platform
Distinguished Investigator / Director of Department of Research Planning and Development
Prof. Tsai studied medicine at Taipei Medical College, Taiwan, before obtaining his Ph.D., at the Division of Human Genetics, Mt. Sinai School of Medicine, City University of New York, USA. Following numerous fellowships through renowned institutions across United States including Division of Medical Genetics, Mt. Sinai Medical Center, New York, USA (1987-1988), Department of Pediatrics, Harvard Medical School, USA (1988-1990), Division of Hematology/Oncology, Children's Hospital, Boston, USA (1988-1990), Prof. Tsai joined the Institute of Genetics, National Yang-Ming University, Taiwan, where he acted as Associate Professor until 1997.
Prof. Tsai then began as a Professor at the Institute of Genetics, National Yang-Ming University, Taiwan, a position he has held for over 20 years. During this time, Prof. Tsai helped the establishment of genome research facility at the National Yang-Ming University and the National Health Research Institutes, acting as Director, Division of Molecular and Genomic Medicine, National Health Research Institutes, Taiwan from 2000 to 2007. Since 2017, Prof. Tsai has been the Director of Department of Research Planning and Development. He has played an active role in leading NHRI research development and engineering key international collaboration programs with Japan and USA. He is the Principle Investigator of the Flagship Program of Precision Medicine for AsiaPacific Biomedical Silicon Valley.
Prof. Tsai's research areas include human genetics, cancer genomics, and microbial genomics. His laboratory has applied genetic mapping and genomic technology to identifying genes associated with human diseases. Using high-throughput genotyping and DNA sequencing, recently, his laboratory has succeeded in discovering the genes responsible for two inherited diseases: type II collagen in osteonecrosis and IL6 receptor family genes in primary cutaneous amyloidosis. Also, he has characterized the genomic alterations associated with lung cancer and liver cancer and investigated the genetic basis determining individual difference in cancer treatment response. In the microbial genomics filed, Professor Tsai is a world expert on several important pathogenic bacteria, including V. vulnificus, K. pneumoniae, A. baumannii, and M. tuberculosis, all of which pose threats to health globally.